Global Peripheral Arterial Disease (PAD) Therapeutics 2018: Worldwide Strategic Business Report – Xarelto Pins Hope on COMPASS and VOYAGER Trials

Dublin, July 11, 2018 (GLOBE NEWSWIRE) — The “Peripheral Arterial Disease (PAD) Therapeutics – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Peripheral Arterial Disease (PAD) Therapeutics in US$ Million.

The report profiles 23 companies including many key and niche players such as:

  • AstraZeneca Plc (UK)
  • Bayer HealthCare Pharmaceuticals (Germany)
  • Bristol-Myers Squibb Company (US)
  • Merck & Co. Inc. (US)
  • Proteon Therapeutics Inc. (US)
  • Sanofi S.A. (France)
  • Symic Bio Inc. (US)
  • TheraVasc Inc. (US)

Key Topics Covered

1. INDUSTRY OVERVIEW
PAD – A Prelude
PAD Statistics
Critical Limb Ischemia – An Insight
High Costs – A Cause of Concern

2. PAD THERAPEUTICS
Anti-Platelet Drugs: Spearheading the Battle against PAD
Key Drugs for Arterial Disease
Clopidogrel (Plavix)
Prasugrel (Effient)
Ticagrelor (Brilinta)
Vorapaxar (Zontivity)
Dual Antiplatelet Therapy (DAPT) for PAD
Entry of Generics Tones Down Growth in Major Markets
Brilinta Fails to Meet Expectations in EUCLID Trial
Xarelto Pins Hope on COMPASS and VOYAGER trials
Other Pipeline Drugs for Peripheral Arterial Disease (PAD)
Cholesterol-Lowering Drugs: A Key Weapon in the Anti-PAD Arsenal

3. MACRO GROWTH DRIVERS
Aging – A Key Driver
High Diabetes Incidence Worldwide: Key Market Opportunity for PAD Therapeutics

4. PERIPHERAL ARTERIAL DISEASE (PAD) – AN OVERVIEW

5. COMPANIES INTO GENE THERAPY FOR PAD
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
CardioVascular BioTherapeutics, Inc. (US)
Celgene Corporation (US)
ID Pharma Co., Ltd. (Japan)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)

6. CLINICAL STUDIES/CORPORATE INITIATIVES
AstraZeneca Announces Results of EUCLID Trial
USPTO Extends Patent Term for Bayer’s Rivaroxaban
Bayer and Janssen Expand Clinical Development Programme for Rivaroxaban
FDA Approves Merck’s Zontivity

7. FOCUS ON SELECT GLOBAL PLAYERS
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)

8. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 23 (including Divisions/Subsidiaries 25)

  • The United States (9)
  • Canada (1)
  • Japan (2)
  • Europe (7)
    • France (1)
    • Germany (2)
    • The United Kingdom (1)
    • Rest of Europe (3)
  • Asia-Pacific (Excluding Japan) (6)

For more information about this report visit https://www.researchandmarkets.com/research/dq76hc/global_peripheral?w=12



CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Cardiovascular Drugs , Cardiology 

Primary Logo

Leave a Comment